Company Introduction (Ticker: CYTO)

Last updated: 2024-04-24

Altamira Therapeutics Ltd., traded under the stock ticker "CYTO", is a biopharmaceutical company that specializes in the discovery, development, and commercialization of novel therapeutics for the treatment of severe respiratory diseases. The company's primary focus is on the development of treatments for patients suffering from idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). Altamira's lead product candidate, Ziritaxestat, is currently in Phase 3 clinical trials for the treatment of IPF. The company also has a pipeline of other drug candidates in various stages of development, targeting different aspects of respiratory diseases. Altamira Therapeutics Ltd. operates on a global scale, with a presence in Europe, the United States, and Asia. The company is committed to scientific innovation and rigorous clinical development to bring new treatment options to patients with limited or no therapeutic options. The company was formerly known as Galapagos NV and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 1999 and is headquartered in Mechelen, Belgium. Altamira Therapeutics Ltd. is a publicly traded company, listed on the NASDAQ Global Select Market under the ticker symbol "CYTO". The company's business model is based on the successful development and commercialization of its drug candidates, either independently or in collaboration with strategic partners.